The Black Book of Psychotropic Dosing and Monitoring
Psychopharmacology Bulletin August 12, 2025 DOI: 10.64719/pb.4493 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Keywords | Dosing Electroconvulsive therapy studies |
| Citations | 15 |
| Key points | Reports that several innovative psychiatric agents have been approved or are near approval, including novel antidepressants, a first-in-class muscarinic agonist for schizophrenia, a psychedelic for PTSD, and a disease-modifying Alzheimer's drug. Three antidepressants launched in 18 months; the first, Auvelity, pairs bupropion with dextromethorphan, which the authors say acts through pharmacokinetic and pharmacodynamic synergy. |
Abstract
Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and the first disease modifying drug for the treatment of Alzheimer’s disease. Three new antidepressants have come to the market in the past 18 months. The first of those, Auvelity, the combination of bupropion and dextromethorphan, takes advantage of a pharmacokinetic and pharmacodynamic synergism between the two drugs.
Citations in the library
Cited by 3
- Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review. Medicina (Kaunas, Lithuania) March 21, 2025
- MDMA for PTSD and beyond: a new paradigm brings hope. Frontiers in Human Neuroscience December 11, 2024
- The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial. European Neuropsychopharmacology June 23, 2025
Cites 11
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression JAMA Psychiatry December 27, 2017
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) The International Journal of Neuropsychopharmacology July 9, 2019
- MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis The Journal of Clinical Pharmacology October 28, 2021
- Hallucinogenic Drugs in Psychiatric Research and Treatment Perspectives and Prospects The Journal of Nervous and Mental Disease March 1, 1995
and 6 more in the library